N-phenylacetylglutamine | 28047-15-6

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 其他氨基酸衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-phenylacetylglutamine
• 英文别名: (phenylacetyl)glutamine；phenylacetyl glutamine；phenylacetylglutamine；phenacetylglutamine；N²-phenylacetyl-glutamine；N²-Phenylacetyl-glutamin；N(2)-phenylacetylglutamine；5-amino-5-oxo-2-[(2-phenylacetyl)amino]pentanoic acid
• CAS: 28047-15-6
• 化学式: C₁₃H₁₆N₂O₄
• mdl: MFCD00425267
• 分子量: 264.281
• InChiKey: JFLIEFSWGNOPJJ-UHFFFAOYSA-N

物化性质

• 熔点：
  85-87?C
• 沸点：
  655.5±55.0 °C(Predicted)
• 密度：
  1.279
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.307
• 拓扑面积：
  110
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 海关编码：
  2924299090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  存储在0-5°C环境中

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Phenylac-Gln-OH
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Phenylac-Gln-OH
CAS number: 28047-15-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H16N2O4
Molecular weight: 264.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

生物活性

Phenylacetylglutamine 是一种结肠微生物代谢产物，来源于氨基酸发酵。具体来说，它是通过谷氨酰胺与苯乙酸的结合形成的，而苯乙酸几乎完全源自苯丙氨酸在微生物作用下的转化。

靶点

• 人类内源性代谢物

体外研究

Phenylacetylglutamine 是一种结肠微生物代谢产物，源于氨基酸发酵。它是通过谷氨酰胺与苯乙酸的结合形成的，并且苯乙酸几乎完全源自于苯丙氨酸在微生物作用下的转化。

反应信息

• 作为产物：
  描述：

  DL-谷氨酰胺 、 苯乙酰氯 在 碳酸氢钠 作用下， 以 水 为溶剂， 生成 N-phenylacetylglutamine
  参考文献：
  名称：

  3-[(Phenylacetyl)amino]-2,6-piperidinedione Hydrolysis Studies with Improved Synthesis and Characterization of Hydrolysates

  摘要：

  In an attempt to clarify ambiguities in earlier reports on the preclinical chemistry of Antineoplaston A10 (3-[(phenylacetyl)amino]-2,6-piperidinedione; PAP), we detail herein hydrolysis studies with improved synthesis and characterization of PAP hydrolysis products, (phenylacetyl)glutamine (PAG), (phenylacetyl)isoglutamine (PAIG), and (phenylacetyl)glutamic acid (PAGA). Flash chromatography proved superior to extraction in the isolation of synthetic standards and hydrolysates. Synthesis of PAIG directly from commercial isoglutamine showed consistently better yields than the previously reported method. The H-1 and C-13 NMR and HPLC-MS data from the synthesized standards matched the data from the isolated PAP hydrolysates formed under acid and alkaline degradation conditions. Multiple quantum coherence NMR methods (HMQC and HMBC) and HPLC-MS-MS methods were applied to provide unambiguous structural assignments for key isomers PAG and PAIG. Previous PAP hydrolysis studies are shown to be reproducible, and the structures of hydrolysis products are elucidated in detail.

  DOI：

  10.1021/js960120y

文献信息

• [EN] DIAGNOSTIC METHODS, THERAPEUTIC AGENTS AND USES THEREOF<br/>[FR] PROCÉDÉS DE DIAGNOSTIC, AGENT THÉRAPEUTIQUES ET LEURS UTILISATIONS
  申请人：METABOLON INC

  公开号：WO2018022866A1

  公开（公告）日：2018-02-01

  The present invention provides a compound of formula (I) or a salt thereof and their use as a biomarker in assessing or monitoring kidney function in a subject, determining predisposition to developing reduced kidney function, classifying a subject according to level of kidney function, diagnosing or monitoring chronic kidney disease. Compositions and method of making of the compound of formula (I) are also described.

  本发明提供了化合物(I)或其盐，并将其用作生物标志物来评估或监测受试者的肾功能，确定发展肾功能减退的易感性，根据肾功能水平对受试者进行分类，诊断或监测慢性肾病。还描述了化合物(I)的组成和制备方法。
• [EN] COMPOUNDS, REAGENTS, AND USES THEREOF<br/>[FR] COMPOSÉS, RÉACTIFS ET UTILISATIONS ASSOCIÉES
  申请人：METABOLON INC

  公开号：WO2019067699A1

  公开（公告）日：2019-04-04

  The present invention provides a compound of formula (I), formula (II), formula (III), (IV) or a salt thereof, compositions and methods of making the compound, methods and reagents for measuring the compound, and kits using the same. The use of a compound of formula (I), formula (II), formula (III), or formula (IV) for assessing or monitoring kidney function in a subject, determining predisposition to developing reduced kidney function, classifying a subject according to level of kidney function, and diagnosing or monitoring chronic kidney disease is also described.

  本发明提供了式(I)、式(II)、式(III)、(IV)或其盐的化合物，以及制备该化合物的组合物和方法，测定该化合物的方法和试剂，以及使用该化合物的工具包。还描述了使用式(I)、式(II)、式(III)或式(IV)的化合物来评估或监测受试者的肾功能，确定发展肾功能减退的易感性，根据肾功能水平对受试者进行分类，以及诊断或监测慢性肾脏疾病。
• Phenylacetylglutamine (PAG) analytical test
  申请人：Abbott Laboratories

  公开号：US05100807A1

  公开（公告）日：1992-03-31

  The present invention is directed to a fluorescence polarization immunoassay for determining the phenylacetylglutamine (PAG) content in body fluids, to the various components needed for preparing and carrying out such an assay, and to the methods of making these components. Specifically, tracers, immunogens and antibodies are disclosed, as well as methods for preparing them. The assay is conducted by measuring the degree of polarization of plane polarized light that has been passed through a solution continuing sample, antiserum and tracer.

  本发明涉及一种用于测定体液中苯乙酰谷氨酰胺（PAG）含量的荧光偏振免疫分析方法，涉及准备和执行此类分析所需的各种组分，以及制备这些组分的方法。具体包括揭示了示踪剂、免疫原和抗体，以及制备它们的方法。该分析通过测量透过含有样品、抗血清和示踪剂的溶液的偏振平面光的偏振度来进行。
• Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
  申请人：Jobdevairakkam Newton Christopher

  公开号：US20070004805A1

  公开（公告）日：2007-01-04

  A process for preparing a stable aqueous dosage form of sodium 4-phenylbutyrate, including such dosage forms in a highly concentrated solution, as well as methods for making 4-phenylbutyrate and 4-phenylbutyric acid, and for using 4-phenylbutyrate. The stable aqueous dosage forms do not freeze at 0° C.

  一种制备稳定的水溶性4-苯基丁酸钠剂量形式的方法，包括高浓度溶液中的这种剂量形式，以及制备4-苯基丁酸钠和4-苯基丁酸的方法，以及使用4-苯基丁酸钠的方法。这些稳定的水溶性剂量形式不会在0℃以下结冰。
• Use of highly concentrated formulations of 4-phenylbutyrate for treatment of certain disorders
  申请人：JOBDEVAIRAKKAM Christopher Newton

  公开号：US20080171792A1

  公开（公告）日：2008-07-17

  A highly concentrated preparation of sodium 4-phenylbutyrate in an aqueous medium as an alternative for present high dosage therapeutic treatments of certain disorders is provided, specifically for the treatment of spinal muscular atrophy (SMA), central nervous system (CNS) cancer, myelodysplastic syndrome (MS), acute leukemia, glioblastoma multiforme, amyotrophic lateral sclerosis (ALS), and colon cancer.

  提供一种高浓度的4-苯基丁酸钠制剂，用作现有高剂量治疗某些疾病的替代品，特别用于治疗脊髓性肌萎缩症（SMA）、中枢神经系统（CNS）癌症、骨髓增生异常综合症（MS）、急性白血病、多形性胶质母细胞瘤、肌萎缩侧索硬化症（ALS）和结肠癌。该制剂以水介质为基础。